Main menu

The ability to understand genomic structural variation through the use of next-generation sequencing promises to deliver crucial diagnostic tools to make personalized medicine a reality. But according to Simon Fraser University's Cenk Sahinalp and his colleagues, the structural variant data that next-generation sequencing produces will be useful — for both drug design and diagnostics — only once recurrent biomarkers in patient subgroups can be identified.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.